정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1346 | Completed | GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study | Diabetes | Drug: Pioglitazone | Phase 4 | Samaritan Health Services | OTHER | 10 | All | 18 Years | Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States |
| 1345 | Recruiting | GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) | SARS-CoV Infection | Drug: GLS-1027 Drug: Placebo |
Phase 2 | GeneOne Life Science, Inc. | INDUSTRY | 132 | All | 18 Years | Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States PHI Clinical Hospital - Shtip, Department for Infectious Diseases and Febrile Conditions, Skopje, North Macedonia PHI General City Hospital "8mi Septemvri" - COVID-19 Intensive Care Department, Skopje, North Macedonia PHI University Clinic for Pulmonology and Allergology, Skopje, North Macedonia PHI University Clinic of Infectious Diseases and Febrile Conditions, Skopje, North Macedonia PHI General Hospital Struga bb, Quay "8-mi Noemvri", Struga, North Macedonia University of Puerto Rico, San Juan, Puerto Rico |
| 1344 | Recruiting | GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) | Infection | Drug: GLS-1200 Drug: Placebo |
Phase 2 | GeneOne Life Science, Inc. | INDUSTRY | 225 | All | 18 Years | Sinus and Nasal Specialists of Louisiana, Baton Rouge, Louisiana, United States University of Pennsylvania, Philadelphia, Pennsylvania, United States Conroe Willis Medical Reasearch, Conroe, Texas, United States |
| 1343 | Recruiting | GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19) | SARS-CoV-2 | Biological: GLS-5310 Biological: Placebo |
Phase 2 | GeneOne Life Science, Inc. | INDUSTRY | 345 | All | 19 Years ~ 65 Years | Korea University Guro Hospital, Seoul, Korea, Republic of |
| 1342 | Not yet recruiting | GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19) | Healthy | Biological: GLS-5130 Biological: Placebo |
Phase 1 | GeneOne Life Science, Inc. | INDUSTRY | 30 | All | 18 Years ~ 65 Years | Clinical Research Puerto Rico, San Juan, Puerto Rico University of Puerto Rico, San Juan, Puerto Rico |
| 1341 | Completed | Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure | COVID-19 Infections | Drug: methylprednisolone therapy Other: Standard care |
Phase 3 | Peking Union Medical College Hospital, Zhongda Hospital, Zhongnan Hospital, Renmin Hospital of Wuhan University | OTHER | 80 | All | 18 Years | Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China |
| 1340 | Recruiting | Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients | Corona Virus Infection | Drug: Dexamethasone Drug: Methylprednisolone |
Phase 4 | Fundacion Instituto de Estudios de Ciencias de la Salud de Castilla y Leon, Instituto de Investigacion Biomedica de Salamanca | OTHER | 290 | All | 18 Years | Complejo Asistencial Universitario de Burgos, Burgos, Spain Complejo Asistencial Universitario de Leon, Leon, Spain Complejo Asistencial Universitario de Salamanca, Salamanca, Spain Hospital Clinico Universitario de Valladolid, Valladolid, Spain Hospital Universitario Rio Hortega, Valladolid, Spain |